NCT06405464View on ClinicalTrials.gov

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

RecruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
HIV Infections
Interventions
DRUG

VOCABRIA 30Mg Tablet

CAB 30 mg Film-coated tablets

DRUG

EDURANT 25Mg Tablet

RPV 25 mg film-coated tablets

DRUG

Cabotegravir Injectable Suspension

CAB LA 600 mg prolonged release suspension for injection (3 mL)

DRUG

Rilpivirine Injectable Suspension

RPV LA 900 mg prolonged release suspension for injection (3 mL)

BIOLOGICAL

Intact proviral DNA assay

HIV-1 latent reservoir size

BIOLOGICAL

Full-length sequencing

Proviral DNA

Trial Locations (1)

8091

RECRUITING

University Hospital Zurich, Zurich

All Listed Sponsors
collaborator

Swiss HIV Cohort Study

NETWORK

lead

University of Zurich

OTHER